{"disease":{"id":"alzheimer-s-disease","name":"Alzheimer's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":16,"pipeline_drug_count":1,"trial_count":21},"drugs":{"marketed":[{"drug_id":"donepezil","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aricept","generic_name":"DONEPEZIL","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Cholinesterase Inhibitor","quality_score":75,"revenue":"800","mechanism":"Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine."},{"drug_id":"lecanemab","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqembi","generic_name":"LECANEMAB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"Amyloid Beta-directed Antibody [EPC]","quality_score":10,"revenue":"500","mechanism":"Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease."},{"drug_id":"florbetaben","indication_name":"Alzheimer’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neuraceq","generic_name":"FLORBETABEN","company_name":"Life Molecular","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"galantamine","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razadyne","generic_name":"GALANTAMINE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Razadyne works by blocking the enzyme that breaks down acetylcholine, allowing more of this neurotransmitter to be available in the brain."},{"drug_id":"flutemetamol","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizamyl","generic_name":"FLUTEMETAMOL","company_name":"Ge Healthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":"Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging."},{"drug_id":"flutemetamol","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizamyl","generic_name":"FLUTEMETAMOL","company_name":"Ge Healthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":"Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging."},{"drug_id":"donepezil-aricept","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"exelon","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exelon","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"rivastigmine","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exelon","generic_name":"rivastigmine","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"aducanumab","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aduhelm","generic_name":"ADUCANUMAB","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"Amyloid Beta-directed Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aricept","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aricept","company_name":"Eisai Korea Inc.","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"aducanumab-avwa","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ADUHELM","generic_name":"ADUCANUMAB-AVWA","company_name":"BIOGEN INC","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"acetylcarnitine","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levocarnitine Acetyl","generic_name":"ACETYLCARNITINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"Carnitine Analog","quality_score":null,"revenue":null,"mechanism":"Acetylcarnitine works by supporting the transport of fatty acids into mitochondria, where they can be used for energy production."},{"drug_id":"epicriptine","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beta-Dihydroergocryptine","generic_name":"EPICRIPTINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"epicriptine","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"lecanemab-irmb","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LEQEMBI","generic_name":"LECANEMAB-IRMB","company_name":"EISAI INC","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"Amyloid Beta-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"florbetapir","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amyvid","generic_name":"FLORBETAPIR","company_name":"Avid Radiopharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":"Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging."},{"drug_id":"florbetapir","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amyvid","generic_name":"FLORBETAPIR","company_name":"Avid Radiopharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":"Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging."},{"drug_id":"ipidacrine","indication_name":"Alzheimer's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amiridine","generic_name":"IPIDACRINE","company_name":"","drug_phase":"phase_2","molecular_target":"Acetylcholinesterase","drug_class":"ipidacrine","quality_score":28,"revenue":null,"mechanism":"Amiridine works by inhibiting the enzyme Acetylcholinesterase, which breaks down the neurotransmitter acetylcholine."},{"drug_id":"florbetaben","indication_name":"Alzheimer’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neuraceq","generic_name":"FLORBETABEN","company_name":"Life Molecular","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":39,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"valacyclovir","indication_name":"Alzheimer's Disease","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."}],"offLabel":[],"totalMarketed":19,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT07205978","title":"Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT02612688","title":"Pragmatic Trial of Video Education in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":197692,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT04701177","title":"Digitally-enhanced, Decentralized, Multi-omics Observational Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Greece 2021 Committee","has_results":false},{"nct_id":"NCT05315895","title":"The Dampness Syndrome of Chinese Medicine Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Guangzhou University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT03653156","title":"China Cognition and Aging Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03621839","title":"New CSF Biomarkers for Alzheimer's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06033066","title":"Financial Incentives and Recruitment to the APT Webstudy","phase":"NA","overall_status":"COMPLETED","enrollment_count":44844,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03657732","title":"The Chinese Familial Alzheimer's Network","phase":"","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06079203","title":"ED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19200,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT07177352","title":"Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":13000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04857060","title":"Palliative Care Educator","phase":"NA","overall_status":"COMPLETED","enrollment_count":11174,"lead_sponsor_name":"Tufts Medical Center","has_results":true},{"nct_id":"NCT01129596","title":"Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-","phase":"","overall_status":"COMPLETED","enrollment_count":10238,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04114994","title":"Longitudinal Cognitive Assessment by BoCA","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Alzheimer's Light LLC","has_results":false},{"nct_id":"NCT06058234","title":"Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study","phase":"","overall_status":"RECRUITING","enrollment_count":8680,"lead_sponsor_name":"Centers for Medicare and Medicaid Services/ Coverage and Analysis Group","has_results":false},{"nct_id":"NCT02162264","title":"Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":8662,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03848312","title":"Preventing Alzheimer's With Cognitive Training","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":7600,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT04426539","title":"New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study","phase":"","overall_status":"COMPLETED","enrollment_count":6061,"lead_sponsor_name":"American College of Radiology","has_results":false},{"nct_id":"NCT01322568","title":"Research on Aging Project in Iceland: Second Stage","phase":"","overall_status":"COMPLETED","enrollment_count":5764,"lead_sponsor_name":"National Institute on Aging (NIA)","has_results":false},{"nct_id":"NCT06322667","title":"A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT04680013","title":"Genetic Studies in Familial Dementia","phase":"","overall_status":"COMPLETED","enrollment_count":4884,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT05153941","title":"Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Altoida","has_results":false},{"nct_id":"NCT01931566","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3494,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07016178","title":"Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research","phase":"NA","overall_status":"COMPLETED","enrollment_count":3454,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT05020106","title":"The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06810960","title":"A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT01867346","title":"Early Markers of Cognitive Change and Alzheimer s Disease","phase":"","overall_status":"COMPLETED","enrollment_count":2850,"lead_sponsor_name":"National Institute on Aging (NIA)","has_results":false},{"nct_id":"NCT07347574","title":"NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Hong Kong University of Science and Technology","has_results":false},{"nct_id":"NCT06922188","title":"Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia","phase":"","overall_status":"RECRUITING","enrollment_count":2460,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT01926249","title":"A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":2325,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06092125","title":"Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT02245737","title":"An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":2218,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02956486","title":"A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2212,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT01739348","title":"An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":2211,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05281744","title":"Collaborative Care Coordination Program for Alzheimer's Disease and Related Dementias","phase":"NA","overall_status":"COMPLETED","enrollment_count":2160,"lead_sponsor_name":"Harvard Pilgrim Health Care","has_results":false},{"nct_id":"NCT05667935","title":"Cognitive Impairment Cohort Study of the Elderly Population in SheMountain","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06043700","title":"A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Eisai Limited","has_results":false},{"nct_id":"NCT03887455","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1906,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT06325527","title":"Cognitive Impairment Cohort Study of the Elderly Population in YuGarden","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1872,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04777409","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1840,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04777396","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1840,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07314190","title":"Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1799,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT02783573","title":"A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1722,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06224725","title":"Acrylamide and Health Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1700,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04241068","title":"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1696,"lead_sponsor_name":"Biogen","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}